Embryonal rhabdomyosarcoma (ERMS) is a tumor of the skeletal muscle in children and is frequently initiated by heterozygous germline mutations in the Hedgehog (Hh) receptor Patched1 (Ptch), both in humans and mice. Using a conditional knock-out strategy in Ptch flox/ þ mice, we demonstrate that early embryonic stages are more susceptible to ERMS development than later stages and that cells normally not committed to undergo myogenesis at this stage represent the major source of ERMS. We found that deletion of a single copy of the Ptch allele at E9.5 using the ubiquitously active Rosa26CreERT2 resulted in a tumor incidence of 88% but reached only 44% and 12% when the Ptch allele was inactivated at E11.5 and E13.5, respectively. Induction of the Ptch mutation at E9.5 did also significantly shorten ERMS-free survival and increased tumor multiplicity compared with tumor induction at E11.5 and E13.5. Interestingly, we observed a more that 10-fold reduction of ERMS incidence when the Ptch mutation was specifically introduced in Myf5-expressing cells, which is the myogenic factor expressed in all muscle cells at E9.5. We conclude that Myf5-negative cells are more susceptible to ERMS development than Myf5-positive embryonic precursors. As the propensity to undergo tumorigenic transformation declined with age, concomitant with the increase of stably committed muscle cells, it seems likely that the Ptch mutation favors tumor formation in progenitor cells, which have not yet acquired a muscle cell fate.
Introduction
Rhabdomyosarcoma is a myogenic tumor and the most common soft tissue sarcoma in children. The embryonal subtype (ERMS, embryonal rhabdomyosarcoma) represents the prevalent subtype and typically occurs in infants and young children. The alveolar subtype (ARMS, alveolar rhabdomyosarcoma) occurs in adolescents and young adults and is most frequently characterized by chromosomal translocation resulting in fusion between PAX3 or PAX7 and the forkhead transcription factor FOXO1 (Merlino and Helman, 1999) . While ARMS most likely arises from postnatal, terminally differentiating myofibres (Keller et al., 2004a, b) , the cellular origin of ERMS is less clear although studies in zebrafish suggested an involvement of satellite cells or myoblasts (Langenau et al., 2007) . Human patients and mice carrying mutations in a single allele of the Hedgehog (Hh) receptor Patched1 (Ptch) show a high incidence of ERMS indicating a pivotal role of the Hh pathway in the pathogenesis of rhabdomyosarcomas (Gorlin, 1987; Hahn et al., 1998; Kappler et al., 2004) .
Ptch plays a negative regulatory role in Hh/Ptch signaling, and mutational inactivation of this gene results in pathological activation of the pathway. This leads to transcriptional activation of Gli1 and Ptch itself, deregulation of cellular proliferation and differentiation, and tumor formation (Hooper and Scott, 2005; Evangelista et al., 2006) . Formation of rhabdomyoblastic tumors in humans and mice harboring a heterozygous germline mutation in Ptch requires an additional mutation, which might be provided by an inactivating mutation or silencing of the remaining wild-type (wt) Ptch allele (Uhmann et al., 2005; Tostar et al., 2006; Ecke et al., 2009) . Sporadic ERMS (in contrast to fusionpositive ARMS) is also characterized by increased Hh signaling as reflected by increased expression of components of the Hh/Ptch signaling pathways such as Gli1 and Ptch, Gli3 and the Gli target Myf5 (Zibat et al., 2010) .
We recently showed that ERMSs of Ptch-mutant mice are not derived from cells constituting postnatal muscle but are most likely initiated before birth (Zibat et al., 2009) . Here, we investigated the cell type and the time point of ERMS initiation during embryogenesis using a conditional Ptch mutation and different Cre-recombinase driver strains. We found that widespread inactivation of a single Ptch allele in Ptch flox/ þ ERT2 þ /À during early embryogenesis resulted in a high tumor incidence during adulthood while restricted inactivation of Ptch in Myf5-positive myogenic cells at the same time point generated only a relatively moderate tumor load. Our results suggest that altered Hh signaling favors ERMS in precursor cells that have not yet acquired a myogenic fate.
Results
High recombination efficiency at the Ptch flox locus after activation of ERT2 in Ptch flox/ þ ERT2 þ /À embryos In order to generate a model for the development of ERMS that allows identification of tumor founder cells we crossed Rosa26CreERT2 (ERT2) females expressing a tamoxifen-inducible Cre-recombinase (Hameyer et al., 2007) with Ptch flox/flox males. To induce the Ptch mutation in the resulting Ptch flox/ þ ERT2 þ /À embryos, the ERT2 þ /À females were injected with 1 mg tamoxifen at different times during pregnancy (see Supplementary material and methods).
We first investigated the onset of ERT2 activity in the embryo after tamoxifen injection. Pregnant females were injected with 1 mg tamoxifen at 9.5dpc. Deletion of Ptch was determined in single Ptch flox/ þ ERT2 þ /À embryos after 12, 24, and 48 h. The number of cells carrying mutant Ptch del alleles reached 83.6 ± 5.4% after 12 h and 90±2.1% and 90.8±1.4% after 24 and 48 h, respectively (Figure 1a) . Cre-mediated recombination of the floxed Ptch locus was accompanied by the appearance of Ptch del transcripts (missing exons 8 and 9 of the wt Ptch transcript) in the respective embryos (Figure 1b) . Apparently, activation of ERT2 and Cre-mediated recombination occurred rapidly and efficiently in embryos after administration of tamoxifen.
Next, we determined the recombination efficiencies of the floxed Ptch locus in DNA from tissues derived from 140-150-day-old Ptch flox/ þ ERT2 þ /À mice, which had been treated with tamoxifen at E9.5, E11.5 or E13.5 during embryogenesis. We also investigated DNA of and Ptch del alleles. (c) Efficiency of loxP recombination at the Ptch locus in DNA from skeletal muscle (sm) of animals treated with tamoxifen at E9.5 (n ¼ 16), E11.5 (n ¼ 15), E13.5 (n ¼ 16) and E13.5/14.5 (n ¼ 9). DNA of a Ptch flox/flox and Ptch del/ þ mouse served as negative and positive controls, respectively. Tam/E: tamoxifen application at embryonic day. The recombination efficiency in (a-c) was calculated as the ratio of the values for the deleted allele to the total value from the floxed allele plus the deleted allele and is denoted in percent. (d) Expression of Ptch transcripts derived from Ptch flox and Ptch del alleles. RT-PCR analyses using cDNA from different organs from 150-day-old Ptch flox/ þ ERT2 þ /À mice, which had been treated with tamoxifen during embryogenesis at E9.5, E11.5, E13.5 or E13.5/14.5. In addition to the wt Ptch and Ptch del transcripts, the normally occuring Ptch mRNA splice variants lacking exon 10 (Nagao et al., 2005) are indicated as well (forward and reverse primer for the analysis were located in Ptch exons 6 and 11, respectively; see also Uhmann et al., 2007) .
Time of initiation of embryonal rhabdomyosarcoma F Nitzki et al mice, which had been treated with tamoxifen at E13.5 and subsequently at E14.5 (hereafter named E13.5/14.5). As shown in Figure 1c , the recombination efficiency in skeletal muscle ranged between 74-100% (n ¼ 14), 69-94% (n ¼ 15), 53-98% (n ¼ 12) and 77-99% (n ¼ 9) in mice induced at E9.5, E11.5, E13.5 or E13.5/E14.5, respectively. The recombination efficiency in DNA of other tissues varied from 70-100% (Supplementary  Table 1 ). It seems likely that the higher variability of the presence of the recombined allele in adult versus embryonic animals is due to varying stochastic expansions of recombined and non-recombined cells. Efficient recombination was also demonstrated by semiquantitative RT-PCR of cDNA derived from the same tissues. Injection of tamoxifen at any embryonal stage resulted in expression of Ptch del transcripts in all examined organs in the adult (Figure 1d ). Expression intensity of mutant Ptch del transcripts in these organs was indistinguishable from Ptch del/ þ mice, in which exons 8 and 9 of Ptch had been deleted in the germline (data for Ptch del/ þ mice have been published before (Zibat et al., 2009) ).
High ERMS incidence after monoallelic loss of Ptch at embryonic day 9.5 We next examined the incidence of tumors in tamoxifentreated and mock-injected control mice. No tumors were found in 21 Ptch flox/ þ ERT2 þ /À control mice derived from untreated females (Table 1) , which excluded unwanted activity of ERT2. One out of 11 Ptch þ / þ and Ptch flox/ þ offspring treated with tamoxifen at E9.5 developed a fibroma and one a lymphoma (Table 1) . Ovarian cysts were discovered in 1 out of 11 Ptch flox/ þ offspring treated with tamoxifen at E13.5/14.5 (Table 1 ). These data show that prenatal tamoxifen application at E9.5 to E13.5/ 14.5, similar to a report by (Diwan et al., 1997) can result in tumor formation in adult mice. However, none of the above-mentioned control animals developed ERMS, which demonstrates that tamoxifen treatment of embryos per se does not predispose to this tumor entity. In contrast, injection of tamoxifen at E9.5 resulted in palpable ERMS in 77% of
mice (n ¼ 17; Table 1 ). The exclusive appearance of ERMS in Ptch flox/ þ ERT2 þ /À mice and the high rate of incidence clearly proved the decisive role of embryonic monoallelic deletion of Ptch in the development of this tumor.
Cre/ þ mice develop ERMS at low incidence The high rate of ERMS induction after widespread monoallelic deletion of Ptch at E9.5 raised the question whether ERMS originated from early myogenic cells. The myogenic factor Myf5 determines the onset of myogenic development and labels all myogenic cells at this developmental stage until expression of MyoD commences (Braun et al., 1994; Gensch et al., 2008) . In addition, expression of Myf5 in the somites and the hypaxial musculature has been reported to depend on active Hh signaling (Gustafsson et al., 2002; McDermott et al., 2005) , which makes Myf5-positive cells an attractive Cre/ þ mice developed ERMS during adulthood, which contrasts to the high rate of ERMS after more widespread inactivation of Ptch at E9.5 in Ptch flox/ þ ERT2 þ /À mice (Table 1) .
In order to demonstrate that the Myf5-Cre-recombinase efficiently deletes the floxed Ptch allele, we determined the appearance of Ptch del alleles in skeletal muscle and other tissues of Ptch flox/ þ Myf5 Cre/ þ mice. In skeletal muscle, diaphragm and muscles of the abdominal wall the recombination efficiency at the floxed Ptch locus was 94, 79 and 85%, respectively (Supplementary Table 2 ). These data show that recombination at the floxed Ptch locus has occurred very efficiently in tissues of myogenic origin in Ptch flox/ þ Myf5 Cre/ þ mice whereas the efficiency in other tissues ranged between 0 and 16.5% (Supplementary Table 2 ). The functionality of the Myf5-Cre-recombinase was also confirmed by morphological examination of Ptch flox/flox
Myf5
Cre/ þ mice. All mice of this genotype died around birth and showed severe developmental abnormalities including defects of the neural tube, the skeleton and the skin (Supplementary Figure 1 ).
Reduced incidence of ERMS after monoallelelic deletion of Ptch at later stages of embryonic development
The relatively high incidence of ERMS after monoallelic inactivation of Ptch in non-myogenic and myogenic precursor cells at E9.5 contrasted sharply with the low incidence of ERMS when Ptch was inactivated in Myf5-expressing committed muscle cells. We reasoned that a stable confinement of cells to the myogenic lineage (such as in Myf5-expressing cells), which goes along with activation of additional regulatory circuits and a more refined cellular phenotype, might impede the ability of Ptch del/ þ cells to undergo subsequent unrestricted proliferation. To test this hypothesis we investigated the incidence of ERMS in animals subjected to monoallelic inactivation of Ptch at later time points.
Interestingly, we found that the number of animals suffering from palpable ERMS decreased to 37% when the Ptch mutation was induced at E11.5 (n ¼ 16; Table 1 ). When the mutation was triggered at E13.5 (n ¼ 17) and E13.5/14.5 (n ¼ 10), the incidence of palpable ERMS further declined to 6 or 0%, respectively (Table 1) . Moreover, induction of Ptch mutation at E11.5, E13.5 and E13.5/E14.5 delayed the onset of palpable ERMS compared with the E9.5 cohort. Median latency times of palpable ERMS (Table 1) and ERMS-free survival curves (Figure 2) clearly indicated a reduced ERMS formation when Ptch was mutated after E9.5. The differences in tumor-free survival were statistically significant according to Gehan's Wilcoxon test, when the E9.5 cohort was compared with the other cohorts (P-values of the E9.5 cohort as compared with E11.5 and E13.5 cohorts were P ¼ 0.000108 and P ¼ 0.00004, respectively. P-value of the E11.5 cohort as compared with the E13.5 cohort was P ¼ 0.03644).
Several mice also developed non-palpable ERMS, which were detected upon autopsy. The incidence of ERMS was 88, 44, 12 and 10% in mice induced at E9.5, E11.5, E13.5 and E13.5/14.5, respectively, when all palpable and non-palpable tumors were included (Table 1) . Furthermore, induction of the Ptch mutation at E11.5, E13.5 and E13.5/14.5 resulted in an average number of tumors of 1.3±0.5, 1 and 1, respectively (Table 2) while inactivation at E9.5 increased the number to an average of 2.5 ± 1.5 per animal. Thus, monoallelic loss of Ptch after E9.5 does not only decrease the incidence but also the multiplicity of ERMS.
All ERMSs of Ptch flox/ þ ERT2 þ /À mice treated with tamoxifen during embryonic development were of the same histology and stained positive for desmin (Supplementary Figure 2 ). In addition, all ERMS showed an almost complete excision of exons 8/9 of the Ptch flox allele (Figure 3a) . This was also demonstrated by genotyping of tumor-derived DNA, which revealed predominance of Ptch del alleles over Ptch flox alleles (Figure 3b ). Besides Ptch del alleles, the tumors still possessed wt Ptch alleles (Figure 3b) . Nonetheless, Ptch transcripts in ERMS were mainly derived from the 
ERT2
þ /À mice after induction of the Ptch mutation at E9.5, E11.5, E13.5 or E13.5/14.5. Ptch flox/ þ ERT2 þ /À mice, in which the Ptch mutation had been induced by tamoxifen at E9.5 (n ¼ 17; Tam E9.5), E11.5 (n ¼ 16; Tam E11.5), E13.5 (n ¼ 17; Tam E13.5) or E13.5/14.5 (n ¼ 10; Tam E13.5/E14.5.5), were monitored weekly for ERMS formation. The differences between the cohorts (except for E13.5 versus E13.5/14.5) were significant (see main text). ERMS of Ptch-mutant mice highly express Hh-target molecules and embryonic muscle markers but not fetal muscle markers As loss of Ptch function should result in activation of Hh downstream signaling events, we measured the expression of Gli1, which reflects activity of the Hh pathway. In fact, Gli1 was overexpressed in the tumors as revealed by quantitative RT-PCR, when compared with normal skeletal muscle (Figure 4a ). In addition, Gli2 and Gli3, and their downstream target during embryonic muscle formation, Myf5 (Gustafsson et al., 2002; McDermott et al., 2005) , were also strongly expressed in ERMS (Figure 4a) .
As the early stages of muscle development seem to be highly susceptible for ERMS development, we also analyzed genes that are differentially expressed by embryonic and fetal myoblasts. During embryonic muscle formation (completed at around E12.5) embryonic myoblasts highly express Pax3 and Pax7. In the course of fetal muscle formation myoblasts are characterized by expression of Itga7, Mck and Pkcy (Biressi et al., 2007a, b) . In agreement with the published data, we detected a strong expression of Pax7 and Pax3 in E9.5 embryos whereas E13.5 embryos strongly expressed Itga7, Pkcy and Mck (Supplementary Figure 3) . Interestingly, all ERMS analyzed contained high levels of Pax3 and Pax7 transcripts (Figure 4b ) but only low levels of the fetal muscle markers Itga7 and Pkcy (Figure 4b ). Mck expression in ERMS did not differ from skeletal muscle. There was no difference in marker gene expression between tumors induced at different embryonic ages (data not shown). Based on the markers analyzed, the expression profile of ERMS from Ptchmutant mice resembled that of embryonic rather than fetal myoblasts. 
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Discussion
In the current study we demonstrate that embryonic cells at E9.5 are more susceptible to Ptch del/ þ -dependent ERMS than cells from later developmental stages. Unexpectedly, we found that only a minority of ERMS originated from committed muscle cells, which express the myogenic factor Myf5, suggesting that uncommitted precursor cells represent the main source of ERMS.
Previous studies from our laboratory revealed that postnatal monoallelic inactivation of Ptch does not suffice to initiate ERMS (Zibat et al., 2009) indicating that cell populations that arise postnatally, such as side population cells, circulating myeloid cells or mesenchymal stem cells of the bone marrow, and satellite cells of the adult skeletal muscle do not contribute significantly to ERMS. Satellite cells have also been excluded by another study in which Cre/Lox inactivation of Ptch using a Pax7-Cre knock-in did not cause ERMS (Taniguchi et al., 2009) . A role of Myf6-positive cells in ERMS formation has been excluded as well (Rivera et al., 2006) .
Although it is virtually impossible to induce ERMS by monoallelic deletion of Ptch in adult mice, embryonic stages are highly susceptible to this type of manipulation. Both, ERMS incidence and ERMS multiplicity peak when the ERMS-driving Ptch mutation is initiated at E9.5 in the mouse. Either parameter is drastically reduced when the mutation is initiated at E13.5 or E13.5/14.5. The reduction in ERMS incidence did not depend on the efficiency of the tamoxifen treatment regimen, as the recombination efficiency at the floxed Ptch locus in skeletal muscle did not differ between cohorts. Furthermore, the very high recombination rate observed in skeletal muscle of some animals in the E13.5 or E13.5/14.5 cohorts did not correlate with ERMS formation (data not shown).
Our finding that some cells at E9.5-but not afterwards-are highly susceptible to ERMS formation raises the question about their identity. Intuitively, one would assume that ERMS arises from muscle cells, which have formed at this stage. Myogenesis at E9.5 is characterized by the expression of Myf5, which is the first myogenic factor activated during development defining the onset of myogenesis (Braun et al., 1992) . Deletion of Myf5 delays myogenesis until E10.5 when expression of MyoD commences (Braun et al., 1994; Gensch et al., 2008) . The expression of Ptch, which is detected in the presomitic and lateral plate mesoderm and in the somites (Goodrich et al., 1996; Hahn et al., 1996; Resende et al., 2010) overlaps with Myf5 expression in the presomitic and paraxial mesoderm (Gensch et al., 2008) , and in the earliest somites in the dermatomyotome (Asakura and Tapscott, 1998) . Moreover, Myf5 expression in the myotome has been reported to depend on Hh signaling and its mediators Gli2 and Gli3 in E9.5 and E10.5 mouse embryos (Gustafsson et al., 2002; McDermott et al., 2005) . Likewise, development of the hypaxial musculature relies on active Hh signaling (Kruger et al., 2001) . It was therefore surprising to see that Ptch flox/ þ Myf5
Cre/ þ mice, which endure heterozygous loss of Ptch in all muscle cells at this stage, develop ERMS only at a low rate. These data clearly suggest that most ERMS originate from a Myf5-negative cell subpopulation, which has not yet acquired a stable myogenic fate. Recently, it has been postulated that highly potent oncogenic events are only tolerated in globally permissive tumor-initiating cells. In contrast, cells which are already committed to a lineage (for example, myogenic stem cells or committed satellite cells in skeletal muscle) are restricted in their permissiveness, and may tolerate only weak oncogenic events (Merlino and Khanna, 2007) . Assuming that this hypothesis is correct and that loss of Ptch function is a highly potent oncogenic event, it is possible that an uncommitted cell, for example, mesodermal cells derived from the presomitic mesoderm, are more poised to develop ERMS in response to the Ptch mutation than more differentiated, for example, a Myf5-expressing myogenic progenitors.
Potential ERMS progenitor cells might also be prone to epigenetic silencing. This assumption is based on the fact that the compound ERMS-initiating event in our model requires silencing of the remaining wt Ptch allele and that Ptch-associated ERMS growth can be abolished alongside with the reexpression of the wt Ptch allele by a combination of the histone deacetylase inhibitor valproic acid and the DNA methyltransferase inhibitor 5-aza-2 0 deoxycytidin (Ecke et al., 2009 ). The role of Hh signaling in the induction of myogenesis raises another tantalizing possibility in this context. Aberrant Hh signaling caused by the lack of a Ptch allele might reduce the efficiency of muscle cell induction and enable Hh signal-receiving cells to respond more readily to tumorigenic cues. The high susceptibility to ERMS at E9.5, the decreased susceptibility at E11.5 and lack of Time of initiation of embryonal rhabdomyosarcoma F Nitzki et al susceptibility at E13.5 in our model nicely fits into this frame. Mesodermal cells that are ready to respond to Hh signaling to form muscle cells at E9.5 have probably adopted a different fate at E11.5 rendering them unresponsive to Hh-induced myogenesis (Varjosalo and Taipale, 2008) . Hence, it becomes more and more difficult to induce ERMS at later stages. Despite these considerations, we are currently not able to distinguish whether ERMS progenitor cells favor silencing of the second Ptch allele or are more responsive to aberrant Hh signaling caused by the Ptch mutation. In fact, both mechanisms might contribute to ERMS formation. It is also difficult to say whether the lack of one Ptch allele promotes uncommitted precursor cells to adopt a myogenic fate during ERMS formation or whether deletion of Ptch initiates tumor formation in cells that have been induced to form muscle cells but still lack a stable myogenic lineage restriction. The expression signature of ERMS, which resembles that of embryonic myoblasts together with the observation that ERMS do not arise in tissues aside from the skeletal muscle system (for example, brain, liver, lung, etc.) in our model, is compatible with both ideas. In any case, formation of Ptch-associated ERMS seems to be different from that of Ptchassociated medulloblastoma, which can be initiated in both stem cells and lineage-restricted progenitors (Yang et al., 2008) .
In summary, our data show that E9.5 embryos are highly susceptible to ERMS formation. The susceptibility declines gradually until the window is closed at around E13.5 during embryogenesis in mice. Our results suggest that ERMS are derived from a cell population at E9.5 in the mouse, which has not acquired a stable myogenic fate as indicated by the expression of Myf5. Although we were not able to determine precisely the exact origin of cells that will give rise to ERMS, the finding that these cells are derived from a population that is permissive to undergo myogenic differentiation but still lacks lineage commitment provides novel important insights into ERMS biology and might help to devise new options for the treatment of ERMS.
Materials and methods
Animals
All experiments were performed using animals with consideration of all necessary legal requirements.
Ptch flox mice on a Balb/cJ background (dominant Balb/cJ alleles confer RMS susceptibility ) were used in the study. Ptch flox mice possess loxP sites flanking Ptch exons 8 and 9, which can be deleted after Cre-mediated recombination. This results in a mutant Ptch del allele (Uhmann et al., 2007) .
Other mouse strains were the Rosa26CreERT2 (ERT2) knock-in strain expressing a ubiquitously expressed tamoxifeninducible Cre-recombinase on a 129Sv background (Hameyer et al., 2007) , and Myf5
Cre/ þ mice on a B6 background containing a Cre-recombinase inserted into the Myf5 locus (Tallquist et al., 2000) . (Uhmann et al., 2007; Zibat et al., 2009) . For genotyping of Myf5Cre, the primer combination 5 0 -CCAGGCTAAGTGCCTTCTCTACA-3 0 /5 0 -AATG CTTCTGTCCGTTTGCCGGT-3 0 was used.
Tamoxifen injection
To activate ERT2 in embryos in utero, ERT2 þ /À females mated to Ptch flox/flox males were injected intraperitoneally with a single dose of 1 mg tamoxifen (10 mg/ml in sterile ethanol/sun flower oil 1:25) at 9.5, 11.5, 13.5 or twice at 13.5 and 14.5 days post coitum (d.p.c.). For determination of embryonic ages, noon on the day of the postcoital plug was taken to be E0.5.
Although it has been reported that a single injection of 1 mg tamoxifen at 9.5 dpc was well tolerated by pregnant females and did not harm the embryos (Danielian et al., 1998) , the lethality of the pups at term was 470% in our pilot tests. Therefore, all fetuses used for postnatal analyses were delivered by cesarean section (E19.5).
To elucidate the period between tamoxifen injection (that is, Cre activation) and onset of the Ptch deletion, Ptch
þ /À embryos were treated with tamoxifen at E9.5 and were isolated 12, 24 or 48 h thereafter.
Tumor monitoring and histological examination
Mice were monitored for tumor formation weekly. If possible, the observation period encompassed at least 250 days. All animals were closely examined after death for additional, nonvisible and non-palpable tumors. The identity of the tumors as RMS was confirmed using paraffin sections stained with hematoxylin and eosin.
DNA and RNA-isolation and quantitative RT-PCR DNA was extracted according to standard procedures. Total RNA was isolated using PeqGOLD TriFast reagent (PeqLab, Erlangen, Germany). Reverse transcription of total RNA was performed using random hexamers and SuperScriptII reverse transcriptase (Invitrogen, Karlsruhe, Germany).
The transcripts derived from the Ptch flox and the Ptch del locus (the latter equates to the floxed Ptch locus after Cre-mediated excision) were analyzed by semiquantitative RT-PCR.
Quantitative RT-PCR was performed on an ABI PRISM 7900HT Sequence Detection System (Applied Biosystems, Darmstadt, Germany). Amplification of 18s rRNA as an endogenous control was performed to standardize the amount of sample RNA.
All primers used in RT-PCR assays are shown in Supplementary Table 3 .
Quantification of ERT2-mediated recombination of the floxed Ptch locus The degree of recombination at the targeted Ptch locus was estimated by real-time PCR in DNA derived from organs of Ptch flox/ þ Myf5
Cre/ þ and Ptch flox/ þ ERT2 þ /À mice and of embryos, which have been treated with tamoxifen in utero. The primers and probes to detect the Ptch flox allele and the Ptch del allele are provided as shown in Supplementary Table 3 . The efficiency of ERT2-mediated recombination at the floxed Ptch locus was quantified by real-time PCR using genomic DNA. The primer combination mPTCdelNx_f/mPTCNx_r amplifies a 160-bp fragment after Cre-mediated excision of
